Guardant Health
Guardant Health, Inc., a leading precision oncology company, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2012, the company has rapidly established itself in the biotechnology industry, focusing on non-invasive cancer detection and monitoring through advanced genomic testing.
Guardant Health is renowned for its flagship product, the Guardant360® test, which provides comprehensive genomic profiling of solid tumours using a simple blood draw. This innovative approach allows for personalised treatment strategies, setting the company apart in the competitive landscape of cancer diagnostics.
With a strong market position, Guardant Health has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to pivotal clinical trials. Its commitment to transforming cancer care through cutting-edge technology continues to drive its success in the oncology sector.
-8 vs industry average
Guardant Health’s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Guardant Health?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Guardant Health's reported carbon emissions
In 2023, Guardant Health, headquartered in the US, reported total emissions of approximately 4,222,000 kg CO2e, comprising 1,659,000 kg CO2e from Scope 1 and 2,563,000 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data. Guardant Health has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, the company has committed to a 42% reduction in absolute Scope 1 and Scope 2 greenhouse gas emissions by 2030, using 2023 as the base year. Furthermore, Guardant Health plans to reduce its Scope 3 emissions from various categories, including purchased goods and services, by 25% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect Guardant Health's commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Guardant Health’s Climate Goals (2030 & 2050)
2 goals2025
We aim to reduce our Scope 1 emissions to near zero by the m…
We aim to reduce our Scope 1 emissions to near zero by the middle of this decade.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsFrequently asked questions
Common questions about Guardant Health’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project